The New York Times Agency May 2010
EN_00917691_8038
(NYT67) NEW YORK -- January 23, 2007 -- BIOTECH-INSURE-2 -- Embrel etanercept for treating psoriasis made by Amgen at Mount Sinai Medical Center in Manhattan on December 8, 2006. Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis. Amgen estimates there are 1.1 million Americans with severe enough psoriasis to warrant one of the biotechnology drugs, which are called biologics because they are manufactured in cultures of living cells. (Hiroko Masuike/The New York Times)
CENA MINIMALNA - 100 USD
2007-01-23
EAST NEWS
The New York Times Agency
Hiroko Masuike
21083268
0,45MB
10cm x 25cm przy 300dpi
1, 2006, 2007, 23, 8, AMERICANS, AMGEN, ARE, AT, BECAUSE, BIOLOGICS, BIOTECHNOLOGY, BY, CALLED, CAN, CELLS, CENTER, CHARGE, COMPANIES, CULTURES, DECEMBER, DRUGS, EMBREL, ENOUGH, ESTIMATES, ETANERCEPT, FOR, HIROKO, HOW, IN, IS, JANUARY, LIMITS, LIVING, MADE, MANHATTAN, MANUFACTURED, MASUIKE, MEDICAL, MILLION, MOUNT, MUCH, NEW, NYT67, OF, ON, ONE, PSORIASIS, REACHING, SEVERE, SIGN, SINAI, SLUGGISH, THAT, THE, THERE, THEY, TIMES, TO, TREATING, WARRANT, WHICH, WITH, YORK,